POPULARITY
5 episodes with clonal hematopoiesis
5 episodes with clonal hematopoiesis
4 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
3 episodes with clonal hematopoiesis
Aging is the leading risk factor for cancer, Alzheimer's, diabetes, and heart disease, and Robert A.J. Signer, Ph.D., studies how aging stem cells shape pre-cancer and healthspan. As deputy director of the Sanford Stem Cell Discovery Center, Signer focuses on rare blood-forming stem cells that self-renew, generate all blood and immune cells, and normally sustain more than 35 trillion blood cells, including about 2 million new red blood cells every second. His group finds that these “Zen” stem cells slow protein production to limit damaging “trash,” but aging stresses overwhelm these defenses. Stress response programs such as HSF1 then help both healthy and mutant stem cells, fueling clonal hematopoiesis, a common, untreated pre-cancerous condition linked to cardiovascular disease, inflammation, cancer, and increased mortality. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41253]
JACC's November 25, 2025 issue kicks off Thanksgiving week with JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, reflecting on his editor's page and the day he became a doctor (0:12). For original research articles, he discusses a study on colchicine & clonal hematopoiesis, an exploratory study of the LoDoCo2 trial (1:10), and a paired editorial comment with more perspectives and a reminder of the upcoming COLCOT trial (4:33). Next, a study on Lp(a) and IL-6 (4:54) and an editorial (6:12), 30-year CVD risk percentiles based on the PREVENT equations (6:30), and an accompanying editorial from JACC Deputy Editor Erica Spatz, MD, on next-generation strategies to encourage healthier behaviors (7:35). Other studies and editorials include a fascinating look at alcohol and blood pressure (8:04) and reinforcing the WHO public health guidance (10:05); remnant cholesterol in young adults (10:38) and implications for cholesterol guidelines (12:36). We also include four brief reports on RSV vaccine (13:11), long Covid (13:43), Lp(a) levels (14:06), the predictive power of polygenic risk scores (14:58), a viewpoint on US veterans (15:36), and our regular Amara Yad image (15:53), which we're delighted to be able to continue to promote with JACC: Clinical Electrophysiology Editor-in-Chief Kalyanam Shivkumar, MD.
In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Clonal Hematopoiesis Is Associated With Adverse Clinical Outcomes and Left Ventricular Remodeling in Aortic Stenosis
Commentary by Dr. Oscar Calvillo-Argüelles.
In this week's episode we'll learn more about how clonal hematopoiesis affects prognosis in patients with telomere biology disorders, consider recently uncovered molecular subtypes of extracutaneous juvenile xanthogranulomas, and discuss a clinical trial of the BCMA-CD3 bispecific antibody teclistamab in patients with relapsed/refractory multiple myeloma who have received previous BCMA-targeted therapy.Featured Articles:Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutationsRecurrent CLTC::SYK fusions and CSF1R mutations in juvenile xanthogranuloma of soft tissueEfficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Jennifer Kwan, MD PhD, and Andrew Nguyen, MD discuss clonal hematopoiesis and the associated risk of cardiotoxicity during solid tumor treatment.
Commentary by Dr. Valentin Fuster
This week, please join author Amy Lin and Statistical Editor Dan (Amanda) Tong as they discuss the article "Clonal Hematopoiesis of Indeterminate Potential With Loss of Tet2 Enhances Risk for Atrial Fibrillation Through Nlrp3 Inflammasome Activation." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20240426.766271
In this week's episode we'll discuss the mechanism by which Jak2V617F clonal hematopoiesis promotes arterial thrombosis, discuss how Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome, and learn more about the clinical and functional features of RAC2-related immunodeficiency.Featured Articles:Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talkStaphylococcus aureus induces drug resistance in cancer T cells in Sézary syndromeClinical and functional spectrum of RAC2-related immunodeficiency
BUFFALO, NY- January 10, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.” In this new editorial, researchers Julieta Elena Rodriguez, Jean Baptiste Micol and Capucine Baldini from Gustave Roussy discuss clonal hematopoiesis. Clonal hematopoiesis (CH) is a term that refers to the presence in blood cells of hematologic malignancy-associated somatic mutations without fulfilling the diagnostic criteria of hematologic disease. Emerging evidence suggests that CH is a consequence of an expansion of cells harboring initiating driver mutations, potentially linked to the aging hematopoietic system. While these detectable somatic mutations are rare in individuals under 40 years old, they become increasingly prevalent in the elderly population, a term called age-related clonal hematopoiesis (ARCH), reaching up to 18.4% in those aged 90 years or older. Aging itself is a significant stressor associated with CH, particularly in individuals over 70 years old. DNMT3A, TET2, and ASXL1 mutations are more common with advancing age. “Recent evidence also indicates that CH may play a role in solid tumors, such as an increased risk of incident lung cancer [4]. While initial studies associated CH mutations with worse survival outcomes [5], newer findings suggest that solid tumor patients with CH may experience longer survival [6]. However, the underlying mechanisms behind this relationship remain to be elucidated.” DOI - https://doi.org/10.18632/aging.205404 Corresponding author - Capucine Baldini - capucine.baldini@gustaveroussy.fr Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205404 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, clonal hematopoiesis, solid tumors About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM
Join us for our first episode of 2024 as we welcome Dr. Alex Bick, Assistant Professor of Medicine in the Division of Genetic Medicine at Vanderbilt University. In this episode, we will explore the impact of clonal hematopoiesis on cancer and cardiovascular health, examine the integration of genomics in healthcare and preventative medicine, and discuss a recent finding from the Million Veterans Program of a modifier variant in APOL1 kidney disease.
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]
The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts... The post iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics appeared first on VJHemOnc.
In this week's episode, we'll learn more about poverty and relapse risk in children with ALL, discuss eligibility criteria and enrollment of diverse racial and ethnic populations in multiple myeloma clinical trials, and learn more about clonal hematopoiesis in VEXAS syndrome.
Dr. Michael Diaz (@mdiazoncmd) and Dr. Namrata Chandhok (@NamrataChandhok) discuss the importance of genomic testing and how to understand and interpret test results when treating patients with myelodysplastic syndromes and clonal hematopoiesis. They also discuss the importance of selecting appropriate therapeutic agents to manage hematologic malignancies. This project is a collaboration between the American Society of Hematology, the Leukemia & Lymphoma Society, and the France Foundation. Access and complete the GENOM modules (for which you can claim CME and MOC credit) via ASH Academy On Demand! Music: "Happy Medium" performed by Zac Nelson, used under license from Shutterstock.
Commentary by Dr. Valentin Fuster
In this week's episode we'll discuss the benefits of early diagnosis and hematopoietic stem cell transplant in patients with hypomorphic RAG deficiency, learn more about EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy, and analyze the associations between clonal hematopoiesis and recurrent vascular events and death in patients with ischemic stroke.
Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.
In this Oncology, Etc. episode, hosts Patrick Loehrer and David Johnson interview hematologist-oncologist and scientist Dr. David Steensma, who currently serves as Head of Global Hematology at Novartis. In Part One of the episode, Dr. Steensma shares about his career journey from astronomy to medicine, and from academia to industry. We'll also learn about the discovery and significance of a new pre-malignant condition - Clonal Hematopoiesis of Indeterminate Potential (CHIP). If you liked this episode, please subscribe. Learn more at https://education.asco.org, or email us at
Commentary by Dr. Valentin Fuster
The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in... The post Clonal hematopoiesis and pre-MDS states appeared first on VJHemOnc.
The relationship between mutations and precursor states in myelodysplastic syndromes (MDS) is a growing area of research, and advances in... The post Clonal hematopoiesis and pre-MDS states appeared first on VJHemOnc.
In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.
Commentary by Dr. Anju Nohria
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Erik Viirre, MD, PhD, Christopher Mason, PhD, Jana Stoudemire, and Brinda Rana, MD, discuss how what we learn from space flight could impact terrestrial health as well as the health of future astronauts. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37559]
Clonal hematopoiesis (CH) is an age-related, asymptomatic condition in which leukemia-associated somatic mutations are detected in the blood of individuals without a hematologic malignancy. In the nontransplant setting, CH is uniformly associated with adverse outcomes, including an elevated risk of developing hematologic malignancies and an increased risk of nonhematologic outcomes because of altered inflammatory signaling. Current evidence has thus been insufficient to resolve disagreement about whether to screen older candidate donors for CH, and some transplant centers have begun excluding donors found to have CH on the basis of the assumption that the adverse associations of native CH also apply in the context of transplant. This study performed a comprehensive analysis of samples from donors age 40 years or older to determine the impact of CH on overall recipient outcomes, risk of DCL, and measures of graft alloimmune activity. Article: https://ascopubs.org/doi/full/10.1200/JCO.21.02286
In the Aging Patient: Dispelling Myths podcast series, Prof Raul Cordoba kicks off a series of podcasts that will offer you up-to-date information about hematology in older adults. For the first interview, he welcomes guest expert Dr Kristina Kirschner to discuss aging and clonal disease. You will learn how clonal hematopoiesis increases with advancing age and how the accumulation of some clonal mutations have been linked with hematological cancers. Dr Kirschner answers questions - asked by patients - about the definition of aging by hematologists, or the relation of aging and susceptibility to clonal cancers. They also address the mechanisms of epigenetic mutations in aging hematopoietic stem cells and the impact of genes drivers of myeloid malignancies in the elderly population. Host: Dr Raul Cordoba; Guest: Dr Kristina Kirschner Additional information (in order of mention): AML (disease): Acute Myeloid Leukemia MDS (disease): Myelodysplastic Syndromes DNMT3A gene (DNA Methyltransferase 3 Alpha) TET2 gene (Tet Methylcytosine Dioxygenase 2) ASXL1 gene (ASXL Transcriptional Regulator 1) CHIP (disease): (Clonal Hematopoiesis of Indeterminate Potential) PPM1D gene: Protein Phosphatase, Mg2+/Mn2+ Dependent 1D What did you think of this podcast? Share your opinions with us in this short feedback survey. https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1 (Provide Feedback) Would you like to receive EBAH CME credit points for listening to this podcast? Please visit the EHA Campus and finalize the quiz questions in the Aging Patient: Dispelling Myths program. https://ehacampus.ehaweb.org/ (https://ehaedu.org/Campus) Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to. Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.instagram.com/EHA_Hematology/) Facebook: https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://e-h-a.link/facebook) LinkedIn: https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://www.linkedin.com/company/eha/) Email us: education@ehaweb.org Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged (https://eha.news/subscribe)
Commentary by Dr. Valentin Fuster
© 2020-2026 Ivy Podcast Discovery LLC
